NASDAQ: ENLVEnlivex Therapeutics Ltd Stock
$1.02-0.03 (-2.86%)
Updated Apr 30, 2025
ENLV Price
$1.02
Fair Value Price
-$0.01
Market Cap
$24.12M
52 Week Low
$0.81
52 Week High
$1.76
P/E
-1.4x
P/B
1.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$13M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENLV Overview
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENLV's potential to beat the market
- ENLV doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENLV
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ENLV news, forecast changes, insider trades & much more!
ENLV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENLV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENLV ($1.02) is overvalued by 8,751.13% relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ENLV ($1.02) is not significantly undervalued (8,751.13%) relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ENLV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENLV due diligence checks available for Premium users.
Valuation
ENLV fair value
Fair Value of ENLV stock based on Discounted Cash Flow (DCF)
Price
$1.02
Fair Value
-$0.01
Undervalued by
8,751.13%
ENLV ($1.02) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENLV ($1.02) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENLV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENLV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.4x
Industry
-162.28x
Market
29.18x
ENLV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
4.45x
ENLV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENLV's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
ENLV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$27.7M
Liabilities
$4.1M
Debt to equity
0.17
ENLV's short-term assets ($25.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENLV's short-term assets ($25.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENLV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENLV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$3.4M
Financing
$1.3M
ENLV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENLV vs Biotech Stocks
Enlivex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.